Multiple sclerosis is a disease of the central nervous system that is associated with leukocyte recruitment and subsequent inflammation, demyelination and axonal loss. Endothelial vascular cell adhesion molecule-1 (VCAM-1) and its ligand, a 4 b 1 integrin, are key mediators of leukocyte recruitment, and selective inhibitors that bind to the a 4 subunit of a 4 b 1 substantially reduce clinical relapse in multiple sclerosis. Urgently needed is a molecular imaging technique to accelerate diagnosis, to quantify disease activity and to guide specific therapy. Here we report in vivo detection of VCAM-1 in acute brain inflammation, by magnetic resonance imaging in a mouse model, at a time when pathology is otherwise undetectable. Antibody-conjugated microparticles carrying a large amount of iron oxide provide potent, quantifiable contrast effects that delineate the architecture of activated cerebral blood vessels. Their rapid clearance from blood results in minimal background contrast. This technology is adaptable to monitor the expression of endovascular molecules in vivo in various pathologies.
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Multiple sclerosis is a disease of the central nervous system characterized by multifocal white matter lesions 1 . At present, the diagnostic criteria for multiple sclerosis, which incorporate both clinical and magnetic resonance imaging (MRI) characteristics, require the demonstration of lesion dissemination in both time and space 2, 3 . Transverse relaxation time (T 2 )-weighted and gadolinium-enhanced longitudinal relaxation time (T 1 )-weighted MRI detects some but not all lesions, whereas advanced MRI techniques such as diffusion imaging 4 , magnetization transfer 5 and magnetic resonance spectroscopy 6 may provide additional insights. These approaches are, however, limited in two key respects: first, they image downstream injury, reflecting relatively advanced pathology; and second, although they provide an indication of severity, they cannot accurately assess disease activity 7 . There is a pressing need for molecular imaging techniques that can identify early pathogenesis to accelerate accurate diagnosis and to guide specific therapy.
VCAM-1 and its ligand, a 4 b 1 integrin (also called very late antigen-4, VLA-4), are important mediators of mononuclear leukocyte recruitment and lesion initiation 8 . VCAM-1 is not constitutively expressed on cerebral vascular endothelium, but is upregulated with endothelial activation 9 . Selective blockade of this interaction in experimental autoimmune encephalitis, the rodent analog of multiple sclerosis, results in abolition of both lymphocyte recruitment and the paralysis that usually follows 10 . Similarly, selective adhesion molecule inhibitors that bind to a 4 b 1 block its association with VCAM-1, resulting in a substantial reduction in both new or enlarging lesions on MRI and clinical relapse in multiple sclerosis 11 . We reasoned that the sensitivity of MRI for detecting early inflammation might be enhanced by using a molecular contrast agent targeted to VCAM-1. Such an approach might potentially provide a more precise and earlier diagnosis, and insights into disease activity, prognosis and response to specific therapy.
Microparticles of iron oxide (MPIO, size range 0.76-1.63 mm) have been used for cellular imaging and tracking 12 . For some molecular imaging applications, the size of these particles would preclude delivery to the target site. For imaging endovascular structures, however, MPIO possess several positive attributes. First, MPIO convey an amount of iron that is orders of magnitude greater than that conveyed by the ultrasmall particles of iron oxide (USPIO) that have been used previously for MRI contrast. Second, the effects of MPIO on local magnetic field homogeneity, and therefore on detectable contrast, extend for a distance roughly 50 times the physical diameter of the microparticle 12 . Third, the size of MPIO means that these particles are less susceptible than USPIO to extravasation or nonspecific uptake by endothelial cells and therefore they retain specificity for molecular targets 13 . Accordingly, we have developed a VCAM-1 antibody-conjugated 1-mm MPIO that shows specific and quantitative binding to activated endothelial cells in culture. We report that, when coupled with MRI, this targeted MPIO contrast agent detects VCAM-1 expression in vivo in mouse brain inflammation with high specificity and exceptional conspicuity. RESULTS VCAM-MPIO bind to TNF-a stimulated sEND-1 cells in vitro Monoclonal antibodies to VCAM-1 were conjugated to 1-mm diameter MPIO (hereafter called VCAM-MPIO). We tested the capacity of this construct for specific and quantitative binding in vitro on cells of a mouse endothelial line (sEND-1) that were exposed to graded doses of tumornecrosis factor-a (TNF-a), an inflammatory stimulus used to provoke surface expression of VCAM-1. After extensive washing, antibody binding to MPIO was quantified under differential interference contrast microscopy. VCAM-MPIO was retained sparsely by unstimulated sEND-1 cells, reflecting low basal expression of VCAM-1. The number of VCAM-MPIO bound to sEND-1 cells increased in response to increasing doses of TNF-a (Fig. 1a,b) . Isotype IgG-MPIO negative control constructs did not bind to TNF-a-stimulated sEND-1 cells. To demonstrate specific retention further, we preincubated VCAM-MPIO with a chimeric protein containing the extracellular domain of VCAM-1 (Fc-VCAM-1). Blocking with this soluble ligand almost completely abolished subsequent VCAM-MPIO retention by TNF-a-stimulated sEND-1 cells. By contrast, pre-incubation with the soluble extracellular domain of intercellular cell adhesion molecule-1 (Fc-ICAM-1) had no effect on VCAM-MPIO retention, as assessed by confocal microscopy (Fig. 1c,d ).
Flow cytometry confirmed that sEND-1 cells had low basal expression of VCAM-1, but showed strong upregulation of VCAM-1 with TNF-a (Fig. 2a) . Pre-incubation of VCAM-1 antibody with soluble Fc-VCAM-1 specifically inhibited VCAM-1 binding, whereas pre-incubation of VCAM-1 antibody with Fc-ICAM-1 had no effect (Fig. 2b,c) .
In vivo MRI detects VCAM-MPIO bound to brain endothelium To induce endothelial activation and VCAM-1 expression in vivo, mice were given interleukin-1b (IL-1b) by unilateral stereotaxic micro-injection to the left striatum. We subsequently administered antibody-MPIO constructs systemically by tail vein injection. Circulation time allowed for both specific binding in the brain and clearance of unbound contrast from the blood. Mice underwent MRI, under general anesthesia, 4.5-5.5 h after injection of IL-1b and 1.5-2.0 h after administration of contrast agent.
VCAM-MPIO caused a marked MRI contrast effect manifest as intensely low signal areas that appeared to delineate blood vessels on the IL-1b-injected side of the brain. Nonspecific retention was almost absent from the non-injected hemisphere (Figs. 3 and 4 and Supplementary Video 1 online). The dynamics of leukocyte-endothelial binding are complex and depend on multiple ligand-receptor interactions. To mimic leukocyte binding more closely, dual antibodyconjugated MPIO were constructed, targeting both VCAM-1 and P-selectin. These dual antibody-conjugated MPIO also bound specifically but did not further enhance contrast effects (Fig. 3b) . Control mice that underwent the same injection regime with an irrelevant isotype antibody-conjugated MPIO showed no contrast effect (Fig. 3c) .
Pre . Antibody binding to VCAM was almost completely abrogated by Fc-VCAM-1, whereas Fc-ICAM-1 had no effect (*P o 0.001).
or with injection of normal saline vehicle only) that received VCAM-MPIO systemically showed no specific contrast effects. To appreciate the extent and architecture of the contrast effect, segmented areas were rendered to create a three-dimensional (3D) volumetric map of contrast binding that clearly demonstrated delineation of vascular structures in the IL-1b-stimulated hemisphere and almost total absence of binding on the contralateral, non-activated side (Fig. 4a) . Pre-treatment to block VCAM-1 abolished VCAM-MPIO retention (Fig. 4b) .
Quantitative analysis of MPIO binding
As compared with brains without IL-1b injection, specific contrast was increased more than 100-fold (3,999 ± 1,959 Â 10 À6 mm 3 versus 36 ± 94 Â 10 À6 mm 3 , mean ± s.d.; P ¼ 0.02) after administration of VCAM-MPIO. No further increase in specific contrast was observed for the dual VCAM and P-selectin antibody-conjugated MPIO (Fig. 4c) .
Distribution of MPIO on histology
Histological examination indicated that VCAM-MPIO lined venules in the IL-1b-stimulated hemisphere (47 ± 15 per section) and showed sparse retention in the contralateral, non-activated hemisphere (3 ± 4, P o 0.0001; Fig. 5 ). MPIO were confined to the lumen of the vessel without extravasation. Isolated MPIO were the most common finding. Small clusters, similar to those seen in vitro, were present in relatively small numbers (Fig. 5b,c) . Phagocytic cells with MPIO within their cytoplasm were occasionally identified. Expression of VCAM-1 was confirmed by immunohistochemistry, showing a distribution that was limited to vascular endothelium (Fig. 5b) .
Safety and tolerability
Injection of antibody-conjugated MPIO was well tolerated in all mice. None of the 16 mice showed signs of ill effect during close observation for up to 5 h after injection. 
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DISCUSSION
We have reported the development and application of a molecular imaging probe that facilitates the identification of VCAM-1 expression in mouse brain in vivo by MRI. The specificity and potency of the contrast effects are marked and derive from a combination of targeted delivery of a large amount of iron oxide to sites of early inflammation and rapid clearance of MPIO from the blood.
The appeals of this approach are manifold. In the context of multiple sclerosis, this technique images a process that occurs early in disease pathogenesis. Unlike existing techniques, our approach does not require tissue destruction or compromise to the blood-brain barrier. Inhibiting the interaction between leukocytes and VCAM-1 has clinical benefit 11 , and the ability to image VCAM-1 raises the possibility of targeting treatment to individuals with increased VCAM-1 expression.
VCAM-1 participates in other inflammatory conditions, including atherogenesis 14, 15 , transplant rejection 16 and cancer 17 , for which therapeutic VCAM-1 targeting may also be effective 18, 19 . More broadly, by modifying the ligand, MPIO constructs could readily be adapted to image other endovascular targets that are differentially expressed in a broad range of pathologies.
Ultrasound has shown promise for imaging endothelial molecules with targeted microbubbles 20 , and an enhanced technique using sensitive particle acoustic quantification has been applied to measure ICAM-1 and VCAM-1 in rat brain 21 . Ultrasound techniques are, however, inherently limited by the need for acoustic windows and ultrasound cannot reliably penetrate human skull. By contrast, MRI provides exquisite spatial resolution and tissue contrast, without ionizing radiation, making it the imaging modality of choice for many brain pathologies and driving the need for molecular magnetic resonance contrast.
Gadolinium-based contrast agents shorten T 1 , providing positive contrast on T 1 -weighted images 22 . Expression of ICAM-1 in rat brain has been imaged ex vivo by using paramagnetic liposomes 23 , and we have targeted E-selectin expression in rat brain in vivo by using a sialyl Lewis x moiety conjugated to Gd-DTPA 24 . The small quantity of gadolinium that can be delivered to an endothelial monolayer, however, limits its contrast effect. By comparison, USPIO provide greater contrast but may require sophisticated ligands that mediate internalization by endothelial cells to achieve adequate local concentrations 25 . USPIO have become popular owing to their long half-life in blood, which is a positive attribute for applications such as the measurement of changes in cerebral perfusion. This property is more of a hindrance in targeted contrast agents, however, because it leads to high background contrast for an extended period. A further potential drawback of USPIO is that contrast is manifest in T 2 *-weighted images as indistinct areas of low signal that can be difficult to distinguish from the ordinary heterogeneity of normal tissue. In addition, because USPIO can be taken up nonspecifically by endothelial cells, there is potential to compromise the specificity of molecular targeting 13 .
MPIO convey an amount of iron that is orders of magnitude greater than USPIO, and cause a local magnetic field inhomogeneity extending for a distance roughly 50 times their physical diameter 12 . Although smaller than leukocytes and thus not prone to small-vessel plugging, MPIO preclude translocation across the endothelium owing to their size and incompressible nature, as confirmed by histology. The pattern of MPIO binding appeared almost identical to the patterns of lymphocyte binding in venules in the rat experimental autoimmune encephalomyelitis model of multiple sclerosis 10 .
Trials have demonstrated clear clinical benefits from inhibition of the interaction between VCAM-1 and its ligand 11 . The ability to image VCAM-1 expression, in conjunction with existing diagnostic approaches, may offer clinically important opportunities to enhance specificity and to accelerate diagnosis. Early diagnosis and delivery of specific guided intervention may improve outcomes and allow response to treatment to be more precisely monitored.
Our approach uses commercially available reagents to provide a generic platform technology for endovascular molecular MRI and potentially allows the substitution of alternative ligands. With respect to translation to clinical use, our approach has three key factors. First, MPIO size. At the doses used here, short-term ill effects were not seen in mice, nor was there evidence of tissue infarction owing to smallvessel plugging. Indeed in vivo imaging and subsequent histological analysis of non-injected hemispheres both confirmed that nonspecific MPIO retention was minor. Second, MPIO composition. The MPIO used here are nonbiodegradable and are not suitable for use in humans. Iron oxide-containing contrast media are, however, in clinical use, and it should be feasible to synthesize biodegradable particles 26, 27 . Third, iron dose. The dose of iron (4.5 mg iron per kg (body weight)) reflects closely the dose of 2.6 mg per kg that has been used extensively for human oncological MRI with USPIO 28 , and is considerably less than that used (30 mg per kg) in a study targeting USPIO to image VCAM-1 in mice 25 .
In conclusion, this molecular imaging approach manifests exceptionally potent contrast effects in MRI. In a mouse model of acute inflammation, cerebral blood vessels were delineated and VCAM-MPIO binding was quantified. Alternative ligand-MPIO constructs provide clear opportunities for diagnostic imaging using specific endothelial cell markers that are differentially expressed in various pathologies, including inflammatory diseases, cancer and atherothrombosis. 
METHODS
Antibody conjugation to MPIO. We used myOne tosylactivated MPIO (1-mm diameter; iron content 26%) with p-toluenesulphonyl (tosyl)-reactive surface groups (Invitrogen) for antibody conjugation. We washed MPIO with sodium borate buffer (0.1 M, pH 9.5) and added purified monoclonal rat antibodies specific to mouse VCAM-1 (clone M/K2, Cambridge Bioscience), IgG-1 (clone Lo-DNP-1, Serotec) or a combination (50/50 wt/wt) of VCAM-1 and P-selectin (clone RB40.34, Fitzgerald Industries; 1 Â 10 9 MPIO per 40 mg of antibody for all). We added 3 M ammonium sulfate to give a final concentration of 1 M. We incubated the solution with constant rotation at 37 1C for 20 h. After incubation, we collected MPIO by using a Dynal magnet (Invitrogen) and discarded the supernatant containing any unbound antibody. We added PBS plus 0.5% BSA and 0.05% Tween 20 (pH 7.4) and incubated MPIO at 37 1C overnight to block the remaining active tosyl sites. We washed MPIO with PBS plus 0.1% BSA and 0.05% Tween 20 at 4 1C before storing at a concentration of 2.5 Â 10 10 MPIO per ml of PBS plus 0.1% BSA and 0.05% Tween 20 at 4 1C. We calculated that the primary amine and sulfydryl groups of 1-mm tosylactivated MPIO have a capacity to bind covalently 1.8 Â 10 9 IgG molecules per MPIO.
Mouse protocol. After anesthesia with isofluorane (2.0-2.5% in 70% N 2 O: 30% O 2 ), adult male NMRI mice (35 ± 2 g) were placed in a stereotaxic frame under a Wild M650 operating microscope (Leica). Using a glass pipette (tip o50 mm), we stereotaxically injected 1 ng of mouse recombinant IL-1b in 1 ml of low endotoxin saline into the left striatum (coordinates from Bregma: anterior 0.5 mm, lateral 2 mm, depth 2.5 mm), to induce endothelial activation. After 3.1 ± 0.2 h, we injected mice through a tail vein with VCAM-MPIO, VCAM+P-selectin-MPIO, or IgG-MPIO (4 Â 10 8 microparticles; B4.5 mg iron per kg; n ¼ 3 per group). We had two control groups of mice (n ¼ 2 per group): in one, mice were injected intracerebrally with 1 ml of low endotoxin saline; in the other, mice were not injected intracerebrally. We subsequently administered VCAM-MPIO intravenously to both control groups.
To determine selectivity of VCAM-MPIO, we injected a further group of mice (n ¼ 3) with 0.2 mg of VCAM-1 antibody per kg at 3.3 ± 0.4 h after intracerebral IL-1b injection to block VCAM-1-binding sites. We subsequently administered VCAM-MPIO 15 min later. After VCAM-MPIO injection, mice were placed in a quadrature birdcage coil with an in-built stereotaxic frame for imaging. We maintained anesthesia with 1.5-1.8% isofluorane in 70% N 2 O/30% O 2 , monitored electrocardiography, and maintained body temperature at B37 1C with a circulating warm water system. All procedures were approved by the UK Home Office.
In vivo MRI. We used a 7-Tesla horizontal bore magnet with an Inova spectrometer (Varian) to acquire a T 2 *-weighted 3D gradient echo data set with the following parameters: flip angle, 351; repetition time, 50 ms; echo time, 5 ms; field of view, 22.5 Â 22.5 Â 31.6 mm 3 ; matrix size, 192 Â 192 Â 360; two averages; total acquisition time, B1 h. The mid-point of acquisition was 1.7 ± 0.5 h after MPIO injection. We serially imaged the same mouse and found maximal contrast at 1-2 h with diminution by 4 h (data not shown).
We zero-filled the data to 256 Â 256 Â 360 and reconstructed it off-line, giving a final isotropic resolution of 88 mm 3 .
MRI analysis. For each magnetic resonance image, we manually masked the brain to exclude extracerebral structures. We segmented low-signal areas in 41 contiguous images, spanning a depth of 3.6 mm from the dorsal hippocampus ventrally. To control for minor variations in absolute signal intensity between individual scans, we calibrated low-signal areas on ten evenly spaced slices per brain. We applied the median signal intensity value to the fully automated, histogram-based batch analysis of the 41-slice sequence. We extracted data for left and right sides of the brain simultaneously with identical parameters. We summated voxel volumes and expressed them as raw volumes in cubic micrometers without surface rendering or smoothing effects. To ensure true laterality, we quantified contrast in each hemisphere 1 mm from the midline outwards. ImagePro Plus (Media Cybernetics) was used to segment and to quantify contrast volume by an operator who was blind to the origin of all data. We present the data as 'specific contrast' , defined as 'left' minus 'right' contrast volume.
Additional methods. Information on cell culture and histology is available in the Supplementary Methods online.
Statistical analysis. Data are expressed as mean ± s.d. and compared, where indicated, by two-tailed t-tests. We assigned statistical significance at P o 0.05.
Note: Supplementary information is available on the Nature Medicine website.
